OFFICIAL LEGAL TITLE
Accelerating Access for Patients Act of 2022
FREQUENTLY ASKED QUESTIONS
What is the official ID of this bill?
The official print number for this legislation is 117_HR_6996.
Which chamber initiated this legislation?
This legislation was initiated in the House of Representatives.
When did the legislative process begin?
The process officially started on 2022-03-08.
What are the main provisions?
Key points include:
- Accelerated Drug Approval: Drugs for serious conditions can be approved faster if early studies show promising results.
- Increased Therapy Availability: Patients with serious illnesses may get quicker access to new, potentially life-saving medications.
- Post-Approval Monitoring: Pharmaceutical companies will need to conduct additional studies after a drug is on the market to confirm its effectiveness and safety.
- Expedited Withdrawal Option: If a drug proves ineffective or unsafe, its approval can be quickly revoked.
What is the specific legal status?
The current status is Expired.
Where can I read the full text of this legislation?
The full official text is available at:
View full text
Who is the primary sponsor?
The primary sponsor is Rep. McMorris Rodgers, Cathy [R-WA-5].
What is the latest detailed status?
The latest detailed status is: Referred to the Subcommittee on Health.
Is this summary verified?
Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.
What is the impact of this bill?
We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge.